Author/Authors :
Yıldız, İbrahim İzmir Katip Çelebi University - Atatürk Training and Research Hospital - Department of Medical Oncology, Turkey , Varol, Umut İzmir Katip Çelebi University - Atatürk Training and Research Hospital - Department of Medical Oncology, Turkey , Şen, Fatma Istanbul University - Institute of Oncology - Department of Medical Oncology, Turkey , Kılıç, Leyla Istanbul University - Institute of Oncology - Department of Medical Oncology, Turkey
Abstract :
Sunitinib is an oral, multi-targeted receptor tyrosine kinase inhibitor (TKI). Based on current data, sunitinib is now one of the preferred drugs for first-line treatment of metastatic renal cell carcinoma (RCC). However, sunitinib may cause various cardiotoxic side effects. Herein, we report a case of cardiac tamponade in a RCC patient treated by sunitinib and discuss the cardiovascular toxicity of sunitinib.